Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-AD in adolescent depression
NCT05814640Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluoxetine, sertraline, vortioxetine, duloxetine, aripiprazole in major depressive disorder (MDD), sponsored by First Affiliated Hospital of Chongqing Medical University. Started Feb 2023; status: recruiting.
02
Drugs
fluoxetinesertralinevortioxetineduloxetinearipiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05814640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814640.